290 related articles for article (PubMed ID: 34128049)
21. Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination among healthcare workers: A tertiary hospital experience in Singapore.
Lim SM; Chan HC; Santosa A; Quek SC; Liu EHC; Somani J
Ann Acad Med Singap; 2021 Sep; 50(9):703-711. PubMed ID: 34625758
[TBL] [Abstract][Full Text] [Related]
22. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.
Baj A; Novazzi F; Genoni A; Ferrante FD; Taborelli S; Pini B; Partenope M; Valli M; Gasperina DD; Capuano R; Prestia M; Spezia PG; Azzi L; Focosi D; Maggi F
Emerg Microbes Infect; 2021 Dec; 10(1):1254-1256. PubMed ID: 34110974
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
Yacoub MR; Cucca V; Asperti C; Ramirez GA; Della-Torre E; Moro M; Zandalasini C; Di Napoli D; Ambrosio A; Signorelli C; Colombo S; Beretta L; Ciceri F; Zangrillo A; Dagna L
Vaccine; 2021 Oct; 39(44):6464-6469. PubMed ID: 34598820
[TBL] [Abstract][Full Text] [Related]
24. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination.
Nishiguchi Y; Matsuyama H; Maeda K; Shindo A; Tomimoto H
BMC Neurol; 2021 Nov; 21(1):452. PubMed ID: 34789193
[TBL] [Abstract][Full Text] [Related]
25. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
26. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study.
Cabezas C; Coma E; Mora-Fernandez N; Li X; Martinez-Marcos M; Fina F; Fabregas M; Hermosilla E; Jover A; Contel JC; Lejardi Y; Enfedaque B; Argimon JM; Medina-Peralta M; Prieto-Alhambra D
BMJ; 2021 Aug; 374():n1868. PubMed ID: 34407952
[TBL] [Abstract][Full Text] [Related]
27. [Anaphylaxis caused by vaccines].
Perea-Valle P; Delgado-Aguirre CJ; Villafuerte-Domínguez BG; Del Río-Navarro BE
Rev Alerg Mex; 2022; 69 Suppl 1():s1-s14. PubMed ID: 34998305
[TBL] [Abstract][Full Text] [Related]
28. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.
Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Zazzi M; Parisi SG
Int J Infect Dis; 2021 Jul; 108():176-178. PubMed ID: 34022329
[TBL] [Abstract][Full Text] [Related]
29. [Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination].
Shibata K; Tanaka H; Otani A; Kubo M; Hasegawa A; Amano I
Rinsho Ketsueki; 2021; 62(10):1519-1521. PubMed ID: 34732627
[TBL] [Abstract][Full Text] [Related]
30. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
Hajissa K; Mussa A
Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
[TBL] [Abstract][Full Text] [Related]
31. A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.
Al-Maqbali JS; Al Rasbi S; Kashoub MS; Al Hinaai AM; Farhan H; Al Rawahi B; Al Alawi AM
Am J Case Rep; 2021 Jun; 22():e932946. PubMed ID: 34117206
[TBL] [Abstract][Full Text] [Related]
32. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
33. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
Abu-Raddad LJ; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R
J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34050372
[No Abstract] [Full Text] [Related]
34. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Pascucci D; Nurchis MC; Sapienza M; Castrini F; Beccia F; D'Ambrosio F; Grossi A; Castagna C; Pezzullo AM; Zega M; Staiti D; De Simone FM; Mores N; Cambieri A; Vetrugno G; Damiani G; Laurenti P
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769618
[TBL] [Abstract][Full Text] [Related]
36. [Not Available].
Klimek L; Chaker AM; Cuevas M
Laryngorhinootologie; 2021 Mar; 100(3):168-173. PubMed ID: 33482671
[TBL] [Abstract][Full Text] [Related]
37. The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.
Shaker M; Phillips E; Blumenthal KG; Abrams EM; Banerji A; Oppenheimer J; Vander Leek TK; Mack DP; Wickner PG; Singer AG; Khan DA; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2556-2561. PubMed ID: 33892171
[TBL] [Abstract][Full Text] [Related]
38. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
39. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
Kadali RAK; Janagama R; Peruru S; Malayala SV
Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
[TBL] [Abstract][Full Text] [Related]
40. Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.
Kim N; Minn D; Park S; Roh EY; Yoon JH; Park H; Shin S
J Korean Med Sci; 2021 May; 36(21):e158. PubMed ID: 34060264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
